Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Attention Deficit Disorder with Hyperactivity | 53 | 2013 | 156 | 6.900 |
Why?
|
Medicaid | 6 | 2025 | 334 | 1.890 |
Why?
|
Accountable Care Organizations | 3 | 2025 | 60 | 1.800 |
Why?
|
Bipolar Disorder | 14 | 2009 | 243 | 1.650 |
Why?
|
Genome-Wide Association Study | 14 | 2018 | 331 | 1.630 |
Why?
|
Central Nervous System Stimulants | 9 | 2013 | 63 | 1.430 |
Why?
|
Methylphenidate | 9 | 2013 | 19 | 1.420 |
Why?
|
Managed Care Programs | 3 | 2025 | 88 | 1.220 |
Why?
|
Child | 47 | 2025 | 4174 | 1.180 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 7 | 2011 | 34 | 0.920 |
Why?
|
Primary Health Care | 3 | 2025 | 643 | 0.890 |
Why?
|
Adolescent | 39 | 2025 | 5824 | 0.830 |
Why?
|
Sexually Transmitted Diseases | 1 | 2023 | 94 | 0.820 |
Why?
|
Genetic Predisposition to Disease | 14 | 2018 | 676 | 0.750 |
Why?
|
MicroRNAs | 6 | 2018 | 616 | 0.730 |
Why?
|
Mental Disorders | 5 | 2021 | 717 | 0.720 |
Why?
|
RNA, Small Nucleolar | 3 | 2017 | 8 | 0.720 |
Why?
|
Medicare Part C | 1 | 2021 | 13 | 0.720 |
Why?
|
Male | 64 | 2025 | 27739 | 0.690 |
Why?
|
Female | 68 | 2025 | 30705 | 0.680 |
Why?
|
Humans | 93 | 2025 | 59360 | 0.670 |
Why?
|
Polymorphism, Genetic | 4 | 2011 | 185 | 0.650 |
Why?
|
Polymorphism, Single Nucleotide | 15 | 2022 | 439 | 0.630 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 5 | 2010 | 23 | 0.580 |
Why?
|
Genotype | 15 | 2014 | 617 | 0.560 |
Why?
|
Blood Platelets | 5 | 2016 | 92 | 0.550 |
Why?
|
RNA, Small Interfering | 3 | 2017 | 857 | 0.520 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 1021 | 0.510 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 6 | 2008 | 17 | 0.500 |
Why?
|
Coronary Disease | 1 | 2017 | 244 | 0.500 |
Why?
|
Age Factors | 12 | 2021 | 1504 | 0.480 |
Why?
|
Brain-Derived Neurotrophic Factor | 3 | 2010 | 30 | 0.480 |
Why?
|
Massachusetts | 9 | 2025 | 2002 | 0.460 |
Why?
|
Blood Pressure | 3 | 2012 | 495 | 0.450 |
Why?
|
Genetic Markers | 3 | 2009 | 116 | 0.450 |
Why?
|
Adult | 33 | 2025 | 15669 | 0.440 |
Why?
|
Temperament | 1 | 2014 | 20 | 0.440 |
Why?
|
Anger | 1 | 2014 | 22 | 0.440 |
Why?
|
United States | 11 | 2025 | 7390 | 0.440 |
Why?
|
Aging | 2 | 2012 | 710 | 0.440 |
Why?
|
Conduct Disorder | 5 | 2009 | 24 | 0.430 |
Why?
|
Irritable Mood | 3 | 2014 | 16 | 0.410 |
Why?
|
Middle Aged | 24 | 2025 | 16317 | 0.400 |
Why?
|
Young Adult | 15 | 2025 | 4267 | 0.400 |
Why?
|
Catechol O-Methyltransferase | 2 | 2009 | 7 | 0.400 |
Why?
|
RNA, Viral | 3 | 2019 | 259 | 0.400 |
Why?
|
Molecular Biology | 2 | 2010 | 66 | 0.390 |
Why?
|
Affective Symptoms | 1 | 2011 | 15 | 0.370 |
Why?
|
Psychiatric Status Rating Scales | 12 | 2009 | 379 | 0.350 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 7 | 2010 | 116 | 0.340 |
Why?
|
Cross-Sectional Studies | 5 | 2025 | 2373 | 0.340 |
Why?
|
Mood Disorders | 5 | 2008 | 69 | 0.330 |
Why?
|
Cognition | 4 | 2012 | 455 | 0.330 |
Why?
|
Executive Function | 1 | 2010 | 61 | 0.330 |
Why?
|
Comorbidity | 15 | 2018 | 1078 | 0.320 |
Why?
|
Family Health | 2 | 2011 | 67 | 0.320 |
Why?
|
Case-Control Studies | 13 | 2011 | 1051 | 0.310 |
Why?
|
Fee-for-Service Plans | 2 | 2021 | 66 | 0.310 |
Why?
|
Hypertension | 2 | 2012 | 568 | 0.310 |
Why?
|
Attention | 1 | 2010 | 146 | 0.300 |
Why?
|
Receptors, Neurotransmitter | 1 | 2008 | 17 | 0.300 |
Why?
|
Child Behavior Disorders | 4 | 2015 | 37 | 0.300 |
Why?
|
Neuropsychological Tests | 7 | 2011 | 371 | 0.300 |
Why?
|
Stroke | 1 | 2017 | 1127 | 0.290 |
Why?
|
Aggression | 4 | 2014 | 52 | 0.290 |
Why?
|
Prevalence | 6 | 2017 | 1252 | 0.280 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2015 | 151 | 0.280 |
Why?
|
Personal Satisfaction | 1 | 2007 | 76 | 0.280 |
Why?
|
Social Determinants of Health | 2 | 2021 | 122 | 0.280 |
Why?
|
Huntington Disease | 2 | 2022 | 146 | 0.270 |
Why?
|
Genome, Human | 4 | 2016 | 224 | 0.270 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2006 | 23 | 0.270 |
Why?
|
DNA, Viral | 2 | 2019 | 223 | 0.270 |
Why?
|
Antipsychotic Agents | 4 | 2014 | 292 | 0.260 |
Why?
|
Brain | 5 | 2015 | 1488 | 0.260 |
Why?
|
Age of Onset | 7 | 2010 | 170 | 0.250 |
Why?
|
Heart Rate | 3 | 2012 | 307 | 0.250 |
Why?
|
Substance-Related Disorders | 4 | 2021 | 682 | 0.250 |
Why?
|
Anxiety Disorders | 8 | 2010 | 186 | 0.250 |
Why?
|
Depressive Disorder, Major | 2 | 2009 | 245 | 0.250 |
Why?
|
Genetic Association Studies | 5 | 2011 | 113 | 0.230 |
Why?
|
Aged | 11 | 2021 | 13416 | 0.220 |
Why?
|
Sex Factors | 5 | 2021 | 935 | 0.220 |
Why?
|
Salaries and Fringe Benefits | 1 | 2023 | 36 | 0.210 |
Why?
|
Gyrus Cinguli | 3 | 2010 | 55 | 0.210 |
Why?
|
Psychiatric Department, Hospital | 1 | 2003 | 6 | 0.210 |
Why?
|
Impulsive Behavior | 1 | 2003 | 28 | 0.200 |
Why?
|
Child, Preschool | 9 | 2017 | 1782 | 0.200 |
Why?
|
Genetic Linkage | 4 | 2011 | 93 | 0.200 |
Why?
|
Frontal Lobe | 3 | 2013 | 64 | 0.200 |
Why?
|
Health Equity | 1 | 2023 | 42 | 0.200 |
Why?
|
Smoking | 2 | 2010 | 826 | 0.200 |
Why?
|
Cognition Disorders | 3 | 2009 | 215 | 0.200 |
Why?
|
Psychotropic Drugs | 1 | 2003 | 81 | 0.190 |
Why?
|
Surveys and Questionnaires | 3 | 2014 | 2513 | 0.190 |
Why?
|
Receptors, Dopamine D4 | 3 | 2011 | 6 | 0.190 |
Why?
|
Infant, Low Birth Weight | 1 | 2002 | 56 | 0.190 |
Why?
|
Maternal Behavior | 1 | 2002 | 31 | 0.190 |
Why?
|
Multimorbidity | 1 | 2021 | 43 | 0.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2017 | 263 | 0.180 |
Why?
|
Follow-Up Studies | 8 | 2012 | 2337 | 0.180 |
Why?
|
Attitude to Health | 1 | 2003 | 279 | 0.180 |
Why?
|
HIV Infections | 2 | 2019 | 913 | 0.180 |
Why?
|
Parietal Lobe | 2 | 2012 | 27 | 0.170 |
Why?
|
Quality of Life | 1 | 2007 | 1137 | 0.170 |
Why?
|
Pregnancy Complications | 3 | 2015 | 364 | 0.170 |
Why?
|
Mothers | 1 | 2003 | 255 | 0.170 |
Why?
|
Psychopathology | 3 | 2009 | 21 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2010 | 806 | 0.160 |
Why?
|
Alcohol Drinking | 1 | 2002 | 288 | 0.160 |
Why?
|
Anxiety | 2 | 2014 | 387 | 0.160 |
Why?
|
Platelet Aggregation | 2 | 2016 | 23 | 0.160 |
Why?
|
Activities of Daily Living | 1 | 2020 | 289 | 0.150 |
Why?
|
Prospective Studies | 7 | 2017 | 3067 | 0.150 |
Why?
|
Cardiovascular Diseases | 3 | 2016 | 788 | 0.150 |
Why?
|
Antigens, Viral | 1 | 2019 | 130 | 0.150 |
Why?
|
Gene Expression | 3 | 2013 | 809 | 0.150 |
Why?
|
Cohort Studies | 4 | 2019 | 2374 | 0.150 |
Why?
|
DNA Viruses | 1 | 2018 | 14 | 0.150 |
Why?
|
Health Care Reform | 1 | 2019 | 84 | 0.150 |
Why?
|
HIV Antibodies | 1 | 2019 | 133 | 0.150 |
Why?
|
Herpesviridae | 1 | 2018 | 14 | 0.150 |
Why?
|
Quality Indicators, Health Care | 1 | 2021 | 332 | 0.150 |
Why?
|
Inflammation | 2 | 2015 | 1099 | 0.150 |
Why?
|
Obesity | 3 | 2017 | 1166 | 0.140 |
Why?
|
Insurance, Health | 1 | 2019 | 133 | 0.140 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 153 | 0.140 |
Why?
|
Depression | 3 | 2014 | 828 | 0.140 |
Why?
|
Hospitalization | 2 | 2014 | 1290 | 0.140 |
Why?
|
Minisatellite Repeats | 3 | 2011 | 6 | 0.140 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 220 | 0.130 |
Why?
|
Siblings | 3 | 2011 | 41 | 0.130 |
Why?
|
C-Reactive Protein | 2 | 2017 | 159 | 0.130 |
Why?
|
Biomarkers | 3 | 2017 | 1306 | 0.130 |
Why?
|
Genetic Variation | 4 | 2012 | 357 | 0.130 |
Why?
|
Soybean Oil | 1 | 2016 | 31 | 0.130 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2015 | 5 | 0.130 |
Why?
|
Anti-Retroviral Agents | 1 | 2016 | 73 | 0.130 |
Why?
|
Internal-External Control | 1 | 2015 | 31 | 0.130 |
Why?
|
Tryptamines | 1 | 2015 | 12 | 0.130 |
Why?
|
DNA Copy Number Variations | 2 | 2016 | 65 | 0.130 |
Why?
|
Phospholipids | 1 | 2016 | 78 | 0.120 |
Why?
|
Metabolic Syndrome | 1 | 2017 | 131 | 0.120 |
Why?
|
Double-Blind Method | 5 | 2010 | 715 | 0.120 |
Why?
|
Diet, Western | 1 | 2015 | 8 | 0.120 |
Why?
|
Thrombosis | 2 | 2015 | 182 | 0.120 |
Why?
|
Reproducibility of Results | 4 | 2012 | 1561 | 0.120 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2006 | 292 | 0.120 |
Why?
|
Chi-Square Distribution | 2 | 2008 | 409 | 0.120 |
Why?
|
Phenotype | 4 | 2017 | 1137 | 0.120 |
Why?
|
Retrospective Studies | 8 | 2019 | 6071 | 0.120 |
Why?
|
HIV-1 | 2 | 2019 | 692 | 0.120 |
Why?
|
Pregnancy, High-Risk | 1 | 2014 | 18 | 0.110 |
Why?
|
Virus Replication | 1 | 2016 | 305 | 0.110 |
Why?
|
Longitudinal Studies | 6 | 2016 | 1189 | 0.110 |
Why?
|
Peripartum Period | 1 | 2014 | 21 | 0.110 |
Why?
|
Atrial Fibrillation | 2 | 2012 | 805 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 2014 | 7 | 0.110 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2014 | 17 | 0.110 |
Why?
|
Receptors, Interleukin-1 Type I | 1 | 2014 | 9 | 0.110 |
Why?
|
Hostility | 1 | 2014 | 15 | 0.110 |
Why?
|
Quinolones | 1 | 2014 | 27 | 0.110 |
Why?
|
Cardiovirus Infections | 1 | 2014 | 14 | 0.110 |
Why?
|
Encephalomyocarditis virus | 1 | 2014 | 15 | 0.110 |
Why?
|
Megakaryocytes | 1 | 2014 | 18 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 6 | 2013 | 2060 | 0.110 |
Why?
|
Platelet Activation | 1 | 2014 | 26 | 0.110 |
Why?
|
Piperazines | 1 | 2014 | 74 | 0.110 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2014 | 45 | 0.110 |
Why?
|
Pregnancy | 5 | 2015 | 2202 | 0.110 |
Why?
|
Insulin Resistance | 1 | 2017 | 392 | 0.110 |
Why?
|
Incidence | 1 | 2017 | 1237 | 0.110 |
Why?
|
Toll-Like Receptor 7 | 1 | 2014 | 95 | 0.110 |
Why?
|
Transcription, Genetic | 2 | 2016 | 844 | 0.110 |
Why?
|
Functional Neuroimaging | 1 | 2013 | 14 | 0.110 |
Why?
|
Quality of Health Care | 1 | 2017 | 510 | 0.110 |
Why?
|
Propylamines | 1 | 2012 | 8 | 0.100 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2012 | 14 | 0.100 |
Why?
|
Toll-Like Receptors | 1 | 2015 | 426 | 0.100 |
Why?
|
Photoplethysmography | 1 | 2012 | 33 | 0.100 |
Why?
|
Alleles | 4 | 2022 | 411 | 0.100 |
Why?
|
Calcium Signaling | 1 | 2014 | 153 | 0.100 |
Why?
|
Receptors, Metabotropic Glutamate | 2 | 2011 | 30 | 0.100 |
Why?
|
Tachycardia | 1 | 2012 | 28 | 0.100 |
Why?
|
Postpartum Period | 1 | 2014 | 182 | 0.100 |
Why?
|
Cell Phone | 1 | 2012 | 42 | 0.100 |
Why?
|
Interleukin-1beta | 1 | 2014 | 258 | 0.100 |
Why?
|
Child of Impaired Parents | 2 | 2009 | 23 | 0.100 |
Why?
|
Echocardiography, Doppler | 1 | 2012 | 131 | 0.100 |
Why?
|
Inheritance Patterns | 1 | 2012 | 18 | 0.100 |
Why?
|
Nerve Net | 1 | 2012 | 93 | 0.100 |
Why?
|
Family | 3 | 2009 | 229 | 0.100 |
Why?
|
Gene Dosage | 1 | 2012 | 60 | 0.100 |
Why?
|
Electric Countershock | 1 | 2012 | 99 | 0.100 |
Why?
|
Interleukin-6 | 1 | 2013 | 310 | 0.100 |
Why?
|
Genetics | 1 | 2011 | 13 | 0.100 |
Why?
|
Intelligence | 1 | 2012 | 55 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2011 | 902 | 0.090 |
Why?
|
Probability | 2 | 2008 | 166 | 0.090 |
Why?
|
Semaphorin-3A | 1 | 2011 | 4 | 0.090 |
Why?
|
Sialoglycoproteins | 1 | 2011 | 21 | 0.090 |
Why?
|
Inpatients | 1 | 2014 | 291 | 0.090 |
Why?
|
Diseases in Twins | 2 | 2010 | 55 | 0.090 |
Why?
|
Receptors, Nicotinic | 1 | 2012 | 66 | 0.090 |
Why?
|
Psychological Tests | 1 | 2011 | 45 | 0.090 |
Why?
|
Risk Factors | 7 | 2023 | 4984 | 0.090 |
Why?
|
Homeostasis | 1 | 2014 | 346 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 49 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 677 | 0.090 |
Why?
|
Heat-Shock Proteins | 1 | 2011 | 65 | 0.090 |
Why?
|
Sodium-Calcium Exchanger | 1 | 2010 | 2 | 0.090 |
Why?
|
Memory Disorders | 1 | 2011 | 48 | 0.090 |
Why?
|
California | 1 | 2011 | 159 | 0.090 |
Why?
|
Administration, Cutaneous | 1 | 2010 | 26 | 0.090 |
Why?
|
Osmosis | 1 | 2010 | 5 | 0.090 |
Why?
|
Membrane Glycoproteins | 1 | 2014 | 661 | 0.090 |
Why?
|
Memory, Short-Term | 1 | 2011 | 59 | 0.090 |
Why?
|
Drug Interactions | 1 | 2010 | 115 | 0.090 |
Why?
|
Gene Regulatory Networks | 1 | 2011 | 147 | 0.090 |
Why?
|
Personality Assessment | 1 | 2010 | 28 | 0.090 |
Why?
|
Valine | 1 | 2010 | 31 | 0.080 |
Why?
|
Risk | 3 | 2010 | 364 | 0.080 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 2 | 1 | 2009 | 1 | 0.080 |
Why?
|
Methionine | 1 | 2010 | 53 | 0.080 |
Why?
|
Twins | 1 | 2010 | 52 | 0.080 |
Why?
|
CLOCK Proteins | 1 | 2009 | 46 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2016 | 5284 | 0.080 |
Why?
|
Glutamine | 2 | 2006 | 46 | 0.080 |
Why?
|
Glutamate Decarboxylase | 1 | 2009 | 21 | 0.080 |
Why?
|
Glutamic Acid | 2 | 2006 | 95 | 0.080 |
Why?
|
Nuclear Family | 1 | 2009 | 17 | 0.080 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2008 | 2 | 0.080 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 1 | 2008 | 9 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 396 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2008 | 23 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2008 | 27 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2015 | 774 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 130 | 0.080 |
Why?
|
Adoption | 1 | 2008 | 2 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2010 | 256 | 0.070 |
Why?
|
3' Untranslated Regions | 1 | 2008 | 89 | 0.070 |
Why?
|
Mice | 6 | 2022 | 10292 | 0.070 |
Why?
|
Wechsler Scales | 1 | 2007 | 15 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 294 | 0.070 |
Why?
|
Social Adjustment | 1 | 2007 | 33 | 0.070 |
Why?
|
Computer Simulation | 1 | 2010 | 458 | 0.070 |
Why?
|
Tandem Repeat Sequences | 1 | 2006 | 26 | 0.070 |
Why?
|
Microsatellite Repeats | 1 | 2006 | 38 | 0.070 |
Why?
|
Risperidone | 1 | 2006 | 24 | 0.070 |
Why?
|
Haplotypes | 3 | 2012 | 115 | 0.070 |
Why?
|
Regression Analysis | 2 | 2008 | 485 | 0.070 |
Why?
|
Signal Transduction | 2 | 2014 | 2902 | 0.070 |
Why?
|
Psychophysiologic Disorders | 1 | 2006 | 7 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2015 | 2050 | 0.070 |
Why?
|
Infant, Newborn | 2 | 2019 | 1283 | 0.070 |
Why?
|
DNA Primers | 1 | 2006 | 289 | 0.060 |
Why?
|
Educational Status | 1 | 2007 | 264 | 0.060 |
Why?
|
Brain Chemistry | 1 | 2006 | 77 | 0.060 |
Why?
|
Marijuana Abuse | 1 | 2005 | 20 | 0.060 |
Why?
|
Meta-Analysis as Topic | 1 | 2006 | 77 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2011 | 850 | 0.060 |
Why?
|
Anti-Anxiety Agents | 1 | 2005 | 31 | 0.060 |
Why?
|
Fluoxetine | 1 | 2005 | 44 | 0.060 |
Why?
|
Substance Abuse Detection | 1 | 2005 | 44 | 0.060 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 259 | 0.060 |
Why?
|
Psychometrics | 2 | 2006 | 362 | 0.060 |
Why?
|
Porphyromonas gingivalis | 2 | 2015 | 16 | 0.060 |
Why?
|
Remission Induction | 1 | 2004 | 137 | 0.060 |
Why?
|
DNA | 1 | 2008 | 806 | 0.060 |
Why?
|
Risk Assessment | 3 | 2009 | 1921 | 0.060 |
Why?
|
Psychological Theory | 1 | 2003 | 25 | 0.050 |
Why?
|
Norway | 2 | 2015 | 18 | 0.050 |
Why?
|
Animals | 6 | 2022 | 19651 | 0.050 |
Why?
|
Sex Distribution | 1 | 2003 | 244 | 0.050 |
Why?
|
Cost of Illness | 1 | 2004 | 156 | 0.050 |
Why?
|
Interview, Psychological | 1 | 2003 | 73 | 0.050 |
Why?
|
Atherosclerosis | 2 | 2015 | 146 | 0.050 |
Why?
|
Infant | 2 | 2019 | 1486 | 0.050 |
Why?
|
Risk Adjustment | 1 | 2023 | 93 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 718 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2003 | 241 | 0.050 |
Why?
|
Neutrophils | 2 | 2015 | 363 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 1093 | 0.050 |
Why?
|
Obstetric Labor, Premature | 1 | 2002 | 31 | 0.050 |
Why?
|
Schools | 1 | 2003 | 150 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2003 | 674 | 0.050 |
Why?
|
Huntingtin Protein | 1 | 2022 | 138 | 0.050 |
Why?
|
Time Factors | 4 | 2010 | 3617 | 0.040 |
Why?
|
Cerebellum | 2 | 2013 | 91 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2003 | 937 | 0.040 |
Why?
|
Europe | 2 | 2011 | 184 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2003 | 741 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 1465 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2010 | 1479 | 0.040 |
Why?
|
Models, Neurological | 2 | 2010 | 79 | 0.040 |
Why?
|
Sustained Virologic Response | 1 | 2019 | 10 | 0.040 |
Why?
|
Prefrontal Cortex | 2 | 2011 | 107 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 2010 | 111 | 0.040 |
Why?
|
Lod Score | 2 | 2008 | 23 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2014 | 1994 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2019 | 72 | 0.040 |
Why?
|
Linkage Disequilibrium | 1 | 2018 | 46 | 0.040 |
Why?
|
Puerto Rico | 1 | 2019 | 134 | 0.040 |
Why?
|
Multifactorial Inheritance | 1 | 2018 | 22 | 0.040 |
Why?
|
Disease Progression | 1 | 2003 | 1122 | 0.040 |
Why?
|
Motivation | 1 | 2020 | 273 | 0.040 |
Why?
|
Dopamine | 2 | 2011 | 102 | 0.040 |
Why?
|
Administration, Oral | 2 | 2010 | 356 | 0.040 |
Why?
|
Prognosis | 2 | 2015 | 1600 | 0.040 |
Why?
|
Antisocial Personality Disorder | 2 | 2009 | 34 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2019 | 446 | 0.030 |
Why?
|
Waist Circumference | 1 | 2017 | 45 | 0.030 |
Why?
|
Demography | 2 | 2008 | 169 | 0.030 |
Why?
|
Creatine | 2 | 2006 | 24 | 0.030 |
Why?
|
Adiposity | 1 | 2017 | 74 | 0.030 |
Why?
|
Medicare | 1 | 2020 | 598 | 0.030 |
Why?
|
Plasma | 1 | 2016 | 35 | 0.030 |
Why?
|
Research Design | 2 | 2010 | 555 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2016 | 93 | 0.030 |
Why?
|
Healthy Volunteers | 1 | 2016 | 66 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 61 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2017 | 205 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 164 | 0.030 |
Why?
|
Cholesterol | 1 | 2017 | 252 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2016 | 191 | 0.030 |
Why?
|
Triglycerides | 1 | 2017 | 231 | 0.030 |
Why?
|
Chlamydophila pneumoniae | 1 | 2015 | 21 | 0.030 |
Why?
|
Time-to-Treatment | 1 | 2016 | 98 | 0.030 |
Why?
|
Migraine Disorders | 1 | 2015 | 39 | 0.030 |
Why?
|
Viral Load | 1 | 2016 | 220 | 0.030 |
Why?
|
Databases, Factual | 1 | 2018 | 813 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 238 | 0.030 |
Why?
|
Interviews as Topic | 2 | 2008 | 481 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2016 | 163 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2015 | 108 | 0.030 |
Why?
|
Overweight | 1 | 2017 | 238 | 0.030 |
Why?
|
Aripiprazole | 1 | 2014 | 5 | 0.030 |
Why?
|
Platelet Count | 1 | 2014 | 25 | 0.030 |
Why?
|
Cell Degranulation | 1 | 2014 | 20 | 0.030 |
Why?
|
Secretory Vesicles | 1 | 2014 | 21 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2015 | 123 | 0.030 |
Why?
|
Bacteroidaceae Infections | 1 | 2014 | 3 | 0.030 |
Why?
|
Platelet Adhesiveness | 1 | 2014 | 5 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2015 | 202 | 0.030 |
Why?
|
Thrombin | 1 | 2014 | 21 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2015 | 170 | 0.030 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2014 | 143 | 0.030 |
Why?
|
Imidazoles | 1 | 2014 | 77 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 527 | 0.030 |
Why?
|
Collagen | 1 | 2014 | 115 | 0.030 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 127 | 0.030 |
Why?
|
Basal Ganglia | 1 | 2013 | 30 | 0.030 |
Why?
|
Pyridines | 1 | 2014 | 98 | 0.030 |
Why?
|
Body Mass Index | 1 | 2017 | 831 | 0.030 |
Why?
|
Atomoxetine Hydrochloride | 1 | 2012 | 6 | 0.030 |
Why?
|
Dietary Fats | 1 | 2014 | 173 | 0.030 |
Why?
|
Insulin | 1 | 2017 | 674 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 188 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2013 | 103 | 0.030 |
Why?
|
Emulsions | 1 | 2016 | 457 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 203 | 0.020 |
Why?
|
PAX5 Transcription Factor | 1 | 2012 | 12 | 0.020 |
Why?
|
Segmental Duplications, Genomic | 1 | 2012 | 1 | 0.020 |
Why?
|
alpha7 Nicotinic Acetylcholine Receptor | 1 | 2012 | 7 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2014 | 258 | 0.020 |
Why?
|
Aptitude | 1 | 2012 | 10 | 0.020 |
Why?
|
Receptor, Metabotropic Glutamate 5 | 1 | 2011 | 8 | 0.020 |
Why?
|
Heart Atria | 1 | 2012 | 135 | 0.020 |
Why?
|
United Kingdom | 1 | 2012 | 69 | 0.020 |
Why?
|
Causality | 1 | 2012 | 57 | 0.020 |
Why?
|
Receptors, Peptide | 1 | 2011 | 31 | 0.020 |
Why?
|
Body Weight | 1 | 2013 | 368 | 0.020 |
Why?
|
NF-kappa B | 1 | 2014 | 460 | 0.020 |
Why?
|
Canada | 1 | 2012 | 147 | 0.020 |
Why?
|
Equipment Design | 1 | 2012 | 329 | 0.020 |
Why?
|
Cadherins | 1 | 2011 | 69 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 152 | 0.020 |
Why?
|
Phosphorylation | 1 | 2014 | 884 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2015 | 1206 | 0.020 |
Why?
|
Recurrence | 1 | 2012 | 603 | 0.020 |
Why?
|
Cytokines | 1 | 2015 | 912 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2011 | 124 | 0.020 |
Why?
|
Length of Stay | 1 | 2014 | 775 | 0.020 |
Why?
|
Gene Deletion | 1 | 2011 | 293 | 0.020 |
Why?
|
Neuroimaging | 1 | 2011 | 143 | 0.020 |
Why?
|
Genetic Testing | 1 | 2011 | 126 | 0.020 |
Why?
|
Netherlands | 1 | 2010 | 22 | 0.020 |
Why?
|
Spain | 1 | 2010 | 32 | 0.020 |
Why?
|
Brain Mapping | 1 | 2011 | 228 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 40 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2009 | 3 | 0.020 |
Why?
|
Germany | 1 | 2010 | 52 | 0.020 |
Why?
|
RNA | 1 | 2013 | 401 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2011 | 589 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 1025 | 0.020 |
Why?
|
Lithium Compounds | 1 | 2009 | 7 | 0.020 |
Why?
|
Cell Line | 1 | 2014 | 1984 | 0.020 |
Why?
|
Receptor, Serotonin, 5-HT1B | 1 | 2009 | 1 | 0.020 |
Why?
|
Receptors, Dopamine D5 | 1 | 2009 | 2 | 0.020 |
Why?
|
Oxygen | 1 | 2011 | 313 | 0.020 |
Why?
|
Pilot Projects | 1 | 2012 | 914 | 0.020 |
Why?
|
Synaptosomal-Associated Protein 25 | 1 | 2009 | 10 | 0.020 |
Why?
|
Reference Values | 1 | 2010 | 326 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 1552 | 0.020 |
Why?
|
Gene Frequency | 1 | 2009 | 118 | 0.020 |
Why?
|
Introns | 1 | 2009 | 104 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2009 | 297 | 0.020 |
Why?
|
Systole | 1 | 2009 | 109 | 0.020 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2008 | 22 | 0.020 |
Why?
|
Diastole | 1 | 2009 | 89 | 0.020 |
Why?
|
Models, Genetic | 1 | 2010 | 255 | 0.020 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2008 | 25 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2009 | 88 | 0.020 |
Why?
|
Social Environment | 1 | 2009 | 91 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 2009 | 133 | 0.020 |
Why?
|
Heterozygote | 1 | 2008 | 161 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2008 | 284 | 0.020 |
Why?
|
Outpatients | 1 | 2008 | 136 | 0.020 |
Why?
|
Algorithms | 1 | 2012 | 976 | 0.020 |
Why?
|
Reaction Time | 1 | 2008 | 119 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 654 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2010 | 279 | 0.020 |
Why?
|
Linear Models | 1 | 2008 | 402 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2008 | 122 | 0.020 |
Why?
|
Enuresis | 1 | 2006 | 1 | 0.020 |
Why?
|
Radiography | 1 | 2008 | 517 | 0.020 |
Why?
|
Genome | 1 | 2009 | 257 | 0.020 |
Why?
|
Logistic Models | 1 | 2010 | 1232 | 0.020 |
Why?
|
Electrocardiography | 1 | 2009 | 523 | 0.020 |
Why?
|
Inositol | 1 | 2006 | 8 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2006 | 24 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2006 | 146 | 0.020 |
Why?
|
Movement Disorders | 1 | 2006 | 22 | 0.020 |
Why?
|
Protons | 1 | 2006 | 60 | 0.020 |
Why?
|
Serotonin | 1 | 2006 | 59 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2006 | 287 | 0.020 |
Why?
|
Drug Synergism | 1 | 2005 | 132 | 0.020 |
Why?
|
Placebos | 1 | 2005 | 68 | 0.010 |
Why?
|
Drug Resistance | 1 | 2005 | 95 | 0.010 |
Why?
|
Benzodiazepines | 1 | 2005 | 94 | 0.010 |
Why?
|
Social Behavior | 1 | 2005 | 87 | 0.010 |
Why?
|
Parents | 1 | 2005 | 367 | 0.010 |
Why?
|